Wockhardt has expanded marketing access to its novel antibiotic Miqnaf (nafithromycin) in India after the Drugs Controller General of India (DCGI) removed a supply condition, the company said in its second-quarter earnings announcement.
The removal of the condition will facilitate access to the drug for a wider patient population, Wockhardt said. The company has deployed a field force for Miqnaf and reported increasing clinical acceptance, citing its pathogen coverage and shorter therapy.
